Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort

Emily R. Kline, Harvard Medical School
Larry J. Seidman, Harvard Medical School
Barbara A. Cornblatt, Zucker Hillside Hospital
Kristen A. Woodberry, Harvard Medical School
Caitlin Bryant, Harvard Medical School
Carrie E. Bearden, University of California Los Angeles
Kristin S. Cadenhead, University of California San Diego
Tyrone D. Cannon, Yale University
Daniel H. Mathalon, San Francisco Veterans Affairs Medical Center
Thomas H. McGlashan, Yale University

Only first 10 authors above; see publication for full author list.

Journal Title: Schizophrenia Research
Volume: Volume 192
Publisher: Elsevier: 12 months | 2018-02-01, Pages 357-363
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.schres.2017.05.032
Permanent URL: https://pid.emory.edu/ark:/25593/tnh33

Final published version: http://dx.doi.org/10.1016/j.schres.2017.05.032

Copyright information:
© 2017 Elsevier B.V.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed October 6, 2019 11:43 PM EDT
Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort

Emily R. Kline\textsuperscript{a,*}, Larry J. Seidman\textsuperscript{a,b}, Barbara A. Cornblatt\textsuperscript{c}, Kristen A. Woodberry\textsuperscript{a}, Caitlin Bryant\textsuperscript{g}, Carrie E. Bearden\textsuperscript{d}, Kristin S. Cadenhead\textsuperscript{e}, Tyrone D. Cannon\textsuperscript{i}, Daniel H. Mathalon\textsuperscript{g}, Thomas H. McGlashan\textsuperscript{h}, Diana O. Perkins\textsuperscript{l}, Ming T. Tsuang\textsuperscript{e}, Elaine F. Walker\textsuperscript{j}, Scott W. Woods\textsuperscript{h}, and Jean Addington\textsuperscript{k}

\textsuperscript{a}Department of Psychiatry, Harvard Medical School at Beth, Israel Deaconess Medical Center, Boston, MA, United States
\textsuperscript{b}Department of Psychiatry, Harvard Medical School at Massachusetts General Hospital, Boston, MA, United States
\textsuperscript{c}Department of Psychiatry, Zucker Hillside Hospital, Long Island, NY, United States
\textsuperscript{d}Departments of Psychiatry and Biobehavioral Sciences and Psychology, UCLA, Los Angeles, CA, United States
\textsuperscript{e}Department of Psychiatry, UCSD, San Diego, CA, United States
\textsuperscript{f}Department of Psychology, Yale University, New Haven, CT, United States
\textsuperscript{g}Department of Psychiatry, UCSF and SFVA Medical Center, San Francisco, CA, United States
\textsuperscript{h}Department of Psychiatry, Yale University, New Haven, CT, United States
\textsuperscript{i}Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States
\textsuperscript{j}Departments of Psychology and Psychiatry, Emory University, Atlanta, GA, United States
\textsuperscript{k}Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada

Abstract

Depressed mood appears to be highly prevalent in clinical high risk (CHR) samples. However, many prior CHR studies utilize modest size samples and do not report on the specific impact of depression on CHR symptoms. The aim of the current paper is to investigate the prevalence of...
depressive disorders and the impact of lifetime depression on baseline clinical presentation and longitudinal outcomes in a large cohort of individuals meeting CHR criteria in the second phase of the North American Prodrome Longitudinal Study (NAPLS-2). Depression was assessed both categorically (via DSM-IV-TR diagnoses) and symptomatically (using a clinician-rated scale of depressive symptoms) within a sample of 764 individuals at CHR and 279 controls. Current and lifetime depressive disorders were highly prevalent (60%) in this sample. Depression diagnoses were associated with more pronounced negative and general symptoms; individuals with remitted depression had significantly less severe negative, disorganized, and general symptoms and better social and role functioning relative to those with current depression. Current mood disturbance, as measured by scores on a clinician-rated symptom scale, contributed beyond the impact of positive and negative symptoms to impairments in social functioning. Both symptomatic and diagnostic baseline depression was significantly associated with decreased likelihood of remission from CHR status; however depression did not differentially distinguish persistent CHR status from transition to psychosis at follow-up. These findings suggest that depressed mood may function as a marker of poor prognosis in CHR, yet effective treatment of depression within this population can yield improvements in symptoms and functioning.

**Keywords**

Mood; Prodrome; Psychosis; Remission; Schizophrenia

1. **Introduction**

Interest in early detection and prevention of schizophrenia and other psychotic disorders has focused attention on teenagers and young adults who may be at risk of developing a psychotic illness. Identifying predictors and mechanisms of transition to psychosis among individuals deemed to be at clinical high risk (CHR) for psychosis is necessary for the development of effective early interventions. Identification and intervention early in the course of psychosis appears to maximize treatment effectiveness and quality of life (Marshall et al., 2005; Woodberry et al., 2016b).

Although criteria for CHR states focus mainly on attenuated psychotic symptoms, depressed mood appears to be highly prevalent in CHR samples. One meta-analysis found that 41% of CHR individuals meet DSM-IV criteria for a depressive disorder (Fusar-Poli et al., 2014). In the first phase of the North American Prodrome Longitudinal Study (NAPLS-1) sample of 377 CHR participants, 55% met DSM-IV criteria for a non-bipolar mood disorder (Woods et al., 2009). The prevalence of depressive symptoms such as dysphoric mood and suicidal ideation in CHR cohorts is likely far higher than the prevalence of diagnosed depressive disorders (Hui et al., 2013). Dysphoric mood appears to contribute uniquely to impairments in social and role functioning (Fulford et al., 2013), and has been associated with poor prognosis (though not necessarily increased conversion to psychosis) within CHR cohorts (Falkenberg et al., 2015; Lim et al., 2015; Schlosser et al., 2012). Thus depression appears to constitute a central clinical feature and risk factor within this already vulnerable population.
The high prevalence of depressed mood within CHR cohorts complicates the conceptualization of CHR youth as primarily ‘prodromal’ to non-affective psychotic disorders. One theory is that depression is a common but ultimately transient feature of the early course of schizophrenia (Häfner et al., 2005). In a review of 23 studies involving 2182 participants at risk for psychosis, only 11% of those who transitioned to psychosis received an outcome diagnosis of affective psychosis (i.e. depression [5%] or bipolar disorder [6%] with psychotic features), and an additional 8% developed schizoaffective disorder (Fusar-Poli et al., 2013). This low proportion of affective disorder outcomes among converters could suggest that although depression is common during a prodromal phase of illness, mood dysfunction remains secondary to emerging psychosis for those at highest risk for conversion.

A different hypothesis holds that the prevalence of depression is high in CHR samples because of the inclusion of individuals with primarily affective disorders who experience waxing and waning subthreshold psychotic symptoms over the course of mood episodes (Sullivan et al., 2014; Wigman et al., 2012); attenuated psychotic symptoms among such individuals may never progress to frank psychosis. Additionally, psychosis occurring in the context of anxiety and depressive disorders may be more common than previously thought (Koyanagi et al., 2016; Wigman et al., 2012). A third potential explanation for the high prevalence of depression in CHR samples is that depressive appraisals of positive symptoms, reduced functioning due to negative symptoms, and/or stigma related to emerging mental illness could trigger depression for individuals experiencing subthreshold psychosis (Krabbendam et al., 2005). In this scenario, depressive mood that follows the onset of attenuated psychotic symptoms further increases the risk of poor outcome through the interactive effects of thought disorder and affect dysregulation; this “negative appraisal” model also aligns with the common clinical observation of depression among patients dealing with shame and loss following a first psychotic episode (Upthegrove et al., 2014). A related conceptualization of the role of depression in psychosis is that depressive symptoms (e.g., dysphoric mood, low self-worth, negative evaluations) exacerbate existing psychotic disorders by worsening distress, pre-occupation, and conviction related to delusional experiences (Smith et al., 2006; Vorontsova et al., 2013); this may be mechanistically related to abnormalities in limbic-prefrontal activity and connectivity observed in schizophrenia spectrum disorders (Phillips and Seidman, 2008). Finally, given evidence for shared genetic etiology (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013), simultaneous emergence of depressive and psychotic symptoms during adolescence may represent a phenotype that is poorly captured by our current nosologic system (Murray and Jones, 2012; Smoller, 2013). In this model, depressed mood may be an intrinsic feature of psychosis even among individuals with “non-affective” or “primary” psychotic disorders (Stochl et al., 2015). The CHR construct likely reflects a heterogeneous population that includes individuals at-risk for worsening psychosis, patients already manifesting the full expression of an affective illness, as well as persons with both symptomatic manifestations.

Despite the body of recent literature describing the prevalence of depression in CHR population, the specific influence of depression on CHR symptom presentation, and the role of depression as a prognostic marker within CHR, is poorly understood. Many prior CHR studies utilize small or modest size samples and do not report on the specific associations.
between depression and attenuated psychosis symptoms. The aim of the current paper is to investigate the prevalence of depressive disorders and the impact of depression on baseline clinical presentation and CHR-status outcomes in the largest cohort of individuals meeting criteria for a CHR syndrome studied to date (NAPLS-2). We also wish to examine whether the impact of depression on symptoms and functioning is better explained by an altered mood “state” vs. a persistent subgroup “trait” model. Informed by models emphasizing shared etiology of mood and psychotic disorders as well as models positing an interactive effect in which psychotic and mood symptoms are seen as mutually exacerbating, we hypothesize that depression is highly prevalent in this CHR sample relative to the control sample, and that CHR participants with a depressive disorder will experience more severe positive and negative symptoms than CHR participants with no depression. An additional exploratory aim is to examine whether the presence of baseline depression may heighten risk for conversion to psychosis over time.

2. Methods

2.1. Sample

The NAPLS-2 sample comprises 764 help-seeking teens and young adults ages 12–35, and 279 controls. Participants were recruited across the eight sites between January 2009 and March 2013. Referrals to the study were made by health care providers, community mental health practitioners, schools, and self/family inquiries. Inclusion/exclusion criteria for the CHR group were: participants met criteria of a prodromal syndrome (COPS) per the Structured Interview for Prodromal Syndromes (SIPS) (McGlashan et al., 2010), or were under age 19 and met criteria for schizotypal personality disorder (SPD). Participants could not meet criteria for a current or lifetime Axis I psychotic disorder (including affective psychoses). Other exclusion criteria were estimated IQ b 70, a central nervous system disorder, or substance dependence in the past 6 months. CHR participants could be included if they met DSM-IV criteria for any other non-psychotic disorder, as long as the disorder did not clearly account for the individual’s prodromal symptoms. Control subjects could not meet criteria for any prodromal syndrome, any current or past psychotic disorder, or a Cluster A personality disorder. They could not have a family history (in first-degree relatives) of any psychotic disorder or any other disorder involving psychotic symptoms.

2.2. Baseline clinical measures

2.2.1. Structured Clinical Interview for Psychosis-Risk Syndromes (SIPS)—

The SIPS is a semi-structured interview targeting interviewees’ experiences of attenuated symptoms and other indicators of psychosis risk (McGlashan et al., 2010; Miller et al., 1999). The SIPS contains probes and rating conventions for 19 symptom constructs, referred to as the Scale of Psychosis-Risk Symptoms or “SOPS.” Items sum to four symptom subscales (positive, negative, disorganized, and general). Each item is rated by the interviewing clinician on a Likert-style scale ranging from zero to six. Reliability was assessed annually based on a video-taped interview. Intraclass correlations, over 4 years, for the total SOPS scores ranged from 0.82 to 0.93 (Addington et al., 2015). The SIPS was administered at baseline and at six, twelve, eighteen, and twenty-four months after study entry.
At follow-up assessments, conversion to psychosis was defined by SIPS presence of psychosis (POPS) criteria (McGlashan et al., 2010). Remission from CHR was defined by failure to meet any of the SIPS psychosis risk syndrome criteria. At follow-up assessments, individuals with “persistent CHR” were those who did not convert to psychosis or remit but continued to experience positive symptoms at a SIPS level of 3–5 even if their symptoms showed no increase in the past year (see Addington et al., 2015).

2.2.2. Structured Clinical Interview for the DSM-IV (SCID-IV)—The structured clinical interview for DSM-IV (SCID) (First, 1995) was used to assess current and lifetime depression as well as other Axis 1 disorders.

2.2.3. Calgary Depression Scale for Schizophrenia (CDSS)—The CDSS (Addington et al., 2007) was used to measure current depressive symptom severity over the past two weeks and has been validated in CHR individuals (Addington et al., 2014).

2.3. Global functioning social and role scales

The social and role functioning scales are clinician-scored scales ranging from 1 to 10. Developmentally appropriate, detailed descriptions are provided to illustrate the range of functioning captured by each point on the scale, with lower scores indicating more impairment (Cornblatt et al., 2007a).

2.4. Demographic and medication logs

The following information was collected through demographic and medication forms: participants’ age, sex, ethnic background, and current and past use of psychotropic medication.

2.5. Analyses

NAPLS-2 baseline assessments were obtained for 1043 participants. Twenty-three participants (20 CHR, 3 controls) had missing SCID diagnoses and were excluded from the current study, leaving a sample of 744 CHR and 276 control participants. Of the remaining 744 CHR participants, 59 (7.9%) had a missing social or role functioning rating; 4 (0.5%) had one or more missing symptom severity ratings on the SIPS; and 24 (3.2%) were missing CDSS scores. Due to the overall low proportion of missing data, individuals with a missing data point were dropped per analysis but retained within the sample; mean substitutions or other imputation methods were not used.

Chi-square tests were performed to compare the prevalence of depression in CHR vs. control groups and to test for significant differences in demographic and medication profiles among participants with and without depression. Multivariate ANOVA controlling for age and gender with Bonferroni correction was used to compare group means on quantitative variables including SOPS ratings and functioning scales. Linear regressions with simultaneous independent variable entry were used to examine the impact of positive, negative, and depressive symptom ratings on current social and role functioning. To avoid construct overlap between independent and dependent variables in the regression, items
reflecting social (N1) and occupational (N6) functioning were removed from negative symptom totals (Meyer et al., 2014).

A one-way ANOVA with Bonferroni corrections was conducted to test for differences in baseline CDSS scores among participants with remitted vs. persistent vs. conversion outcomes. Chi-square tests were used to examine the relative likelihood of the three categorical outcomes among participants with and without a current or past diagnosis of depression at baseline.

3. Results

CHR participants’ mean age was 18.5 years (19.8 for controls), with 11.3 years of education (12.7 for controls). Fifty-seven percent of those at CHR and 50% of controls were male. Thirty-seven percent of CHR and 40% of controls identified as non-white, and 19% of CHR and 18% of controls were Hispanic/Latino. The vast majority (95% of each group) were never married. The majority reported that they resided with family (76% of CHR, 63% of controls). Addington et al. (2015) present complete NAPLS-2 demographic information (one control participant was subsequently dropped from the original sample due to a previously unknown family history of psychosis).

Sixty percent of CHR subjects and 7% of controls had a lifetime (current OR past) diagnosis of a unipolar depressive disorder ($\chi^2 [1,1020] = 223.19, p < 0.001$); 42% of CHR and 4% of controls met DSM-IV criteria for current depression at the time of their baseline assessment ($\chi^2 [1,1020] = 157.37, p < 0.001$). An additional 56 participants met DSM-IV criteria for a bipolar mood disorder; these individuals were not included in the “depressed” subgroup (Fig. 1). Major depressive disorder (MDD) was the most common diagnosis, accounting for 77% of lifetime depressive disorder diagnoses within the CHR group (Fig. 1). Among the 444 CHR participants with a lifetime diagnosis of a depressive disorder, 314 met criteria for a current diagnosis of depression, with the other 130 cases meeting criteria for remitted depressive episodes.

CHR participants with a lifetime diagnosis of unipolar depression (MDD, dysthymic disorder, or depression NOS) were somewhat older (18.9 vs. 18.0; $t [df = 742] = −2.77, p = 0.006$) relative to those with no lifetime depression diagnosis. Women in the cohort had a higher lifetime prevalence of depression than men (64% vs. 56%; $\chi^2 [1744] = 4.62, p = 0.032$). There was no significant difference in the lifetime prevalence of depression among white vs. non-white participants (60% vs. 60%), Asian vs. non-Asian participations (57% vs. 60%), or Hispanic vs. non-Hispanic participants (64% vs. 59%). Black participants had significantly lower lifetime prevalence of depression than non-black participants (50% vs. 62%; $\chi^2 [1743] = 5.33, p = 0.021$). Participants who identified more than one ethnicity had higher lifetime prevalence of depression (70%) than those who identified a single ethnic category (58%) ($\chi^2 [1743] = 4.54, p = 0.033$).

Individuals with a current or past depressive disorder presented at baseline with greater exposure across multiple categories of psychiatric medications relative to non-depressed individuals in the CHR cohort. Specifically, those with depression were significantly more
likely to have taken antidepressants or any type of psychotropic medication, and less likely to have taken mood stabilizers, relative to those without depression (Table 1).

Relative to never-depressed CHR subjects, those with current or past depression presented with significantly more severe negative and general symptoms, and greater impairments in social functioning, but no significant differences in positive or disorganized symptoms or role functioning (Table 2). Relative to those with current depression at the time of assessment, those with remitted depression had less severe negative, general, and disorganized symptoms, as well as better role and social functioning. Using the continuous data (i.e., CDSS), there was a moderate positive correlation of $r = 0.35$ ($p < 0.001$) of depression with SIPS negative symptom total scores. Remitted vs. currently depressed subjects did not differ with regard to positive symptom presentation (Table 2).

Within the full CHR sample, participants’ continuously-rated depressive symptoms contributed uniquely to social functioning impairments beyond the impact of positive and negative psychosis-related symptoms (Table 3). This was also true when the impact of depression, positive, and negative symptoms was examined only among those with a current or past depression diagnosis (Table 3).

Follow-up SIPS diagnoses were available for 559 (73%) of CHR participants (a detailed description of longitudinal outcomes has been reported in a prior publication (Addington et al., 2015)). An ANOVA analyzing mean differences in CDSS scores between the three outcome groups (remitted, persistent or converted) was significant ($F \{2, 2549\} = 4.77, p = 0.009$). Comparisons revealed that CHR-remitted subjects had significantly lower baseline CDSS scores relative to those with persistent CHR. Further, participants with a lifetime diagnosis (past or present) of depression tended to be less likely to achieve CHR remission than those with no history of depression ($\chi^2 \{1558\} = 3.76, p = 0.052$); however, depression diagnoses were not significantly associated with increased risk for conversion ($\chi^2 \{1558\} = 0.01, p = 0.926$). Antidepressant medication exposure at baseline did not predict CHR-status outcomes (i.e., remission/persistence/conversion) among the CHR subgroup with a current or past depression diagnosis ($\chi^2 \{2334\} = 0.473, p = 0.789$). The prevalence of lifetime substance use disorders did not differ significantly between CHR participants with and without a depressive disorder (22% vs. 18%; $\chi^2 \{1744\} = 1.20, p = 0.272$).

4. Discussion

In the largest and most detailed study of CHR prodromal cases to date, we demonstrated that unipolar depressive disorders were highly prevalent among participants in the NAPLS-2 baseline cohort. Three hundred and sixteen (42%) met DSM-IV criteria for a current depressive disorder, and an additional 133 (18%) met criteria for past depression currently in remission. Most of these participants met criteria for Major Depressive Disorder as opposed to dysthymia or depression “NOS,” indicating a high frequency of serious mood disturbance. Relative to never-depressed subjects, CHR participants with current or past depression

---

1This analysis was also conducted controlling for age, sex, and multi-ethnic identity; in the corrected model, differences in CDSS scores among the outcome groups remained significant.
presented with more prior exposure to psychotropic medications (in particular, antidepressants), which could reflect a greater tendency toward seeking mental health treatment (for any reason) among CHR individuals suffering from dysphoric mood (Falkenberg et al., 2015). NAPLS participants with depression were also previously shown to have higher rates of prior psychosocial treatment in addition to pharmacologic treatment, and generally sought treatment prior to the observed onset of their psychosis-risk symptoms (Woodberry et al., 2016a).

The lower prevalence of depression among Black participants is consistent with national data reflecting somewhat lower lifetime prevalence of major depression within Black Caribbean (12.9%) and African American (10.4%) populations relative to whites (17.9%) in the United States general population (Williams et al., 2007). The higher prevalence of depression among multi-ethnic and female participants also reflects national trends (Fisher et al., 2014; Kessler et al., 2005).

With regard to attenuated psychotic symptoms, participants with current or past depression presented with significantly worse negative and general symptoms than those without depression. Further, these symptoms as well as disorganized symptoms also varied significantly between individuals with a current vs. remitted depressive episode. This finding potentially supports a ‘state’ interpretation, i.e. that current mood state accounts for considerable variation in an individual’s CHR symptom profile. Positive symptoms, however, were unassociated with either ‘state’ or ‘trait’ mood differences. One clinical implication of this finding may be that treatments targeting depression in CHR patients are likely to alleviate general, disorganized, and negative – but not necessarily positive – symptoms.

Within the NAPLS-2 sample, both depression and negative symptoms impacted functioning. The negative correlates of mood disturbance – both within the entire CHR sample, and within the ever-depressed subsample – were more pronounced for social than for role functioning. Individuals with remitted depression were comparable in role functioning to their never-depressed peers. Although depression did contribute uniquely to impairments in social functioning, it was not as strong a predictor of functioning as negative symptoms. The critical impact of negative symptoms on social and occupational functioning is well documented within both clinical high-risk samples (Corcoran et al., 2011; Meyer et al., 2014; Schlosser et al., 2015) and established psychosis (Albert et al., 2011; Gee et al., 2016; Milev et al., 2005; Stouten et al., 2015). Research on treatment effects in first episode psychosis, however, indicates that effective treatment of depression within this population may be a key mediator of changes in social and role functioning (Minor et al., 2015). Studies of treatment of depression in CHR samples are naturalistic and not controlled trials (Cornblatt et al., 2007b), suggesting a need for new trials of depression treatment within this population. It is possible that the additional treatment received by those with a history of depression may have been protective against conversion in some cases; more research is needed to systematically explore depression-targeted treatments for the prevention of psychosis progression in CHR populations.
The current study replicated prior findings that comorbid depression (dimensional or diagnostic) is not associated with increased risk of conversion to psychosis (Lim et al., 2015; Rutigliano et al., 2016). However, by examining likelihood of remission as well as conversion, this study offers a novel finding as well: that the relative absence of depression did predict remission of attenuated psychotic symptoms on follow-up. In other words, participants without a diagnostic history of depression and low baseline depression symptoms were more likely to experience a resolution of their CHR syndrome compared to more depressed participants. This finding replicates the earlier observation of Schlosser et al. (2012) and lends support to models that emphasize shared genetic risk and simultaneous emergence of co-occurring disorders (Stochl et al., 2015) as well as models that regard depression as an additional risk factor for psychosis (Wigman et al., 2012). These data do not support the conceptualization of depression as primarily a reaction to psychosis, as even a diagnosis of MDD in remission was associated at a trend level with lower likelihood of future CHR remission.

It is difficult to compare the prevalence and impact of depression within CHR vs. established psychosis samples because existing categorization strategies for disorders involving psychotic symptoms typically seek to characterize mental disorders as ‘primarily’ affective vs. psychotic in nature. The temporal relationship of affective and psychotic symptoms was not assessed in this cohort and may still be evolving even during a first episode of psychosis. Thus, the prognostic meaning of depression within first-episode psychosis remains unclear. Although some studies report that the presence of depression in non-affective first episode psychosis is associated with worse functioning and more difficulty in recovery (Chang et al., 2015), affective psychoses are generally thought to be more responsive to treatment and less chronically impairing than nonaffective psychotic disorders (Tohen et al., 2000). Further complicating this picture is the issue of diagnostic instability early in the course of psychotic illness. One prospective study found that only 47% of DSM-IV diagnoses of major depression with psychotic features remained consistent after 10 years; many of these cases had ‘migrated’ into a schizophrenia diagnosis over time (Heslin et al., 2015), thus potentially lending support to the theory that depression with psychotic features may in fact represent prodromal schizophrenia. In sum, the extremely high prevalence of depression in both the current CHR sample and the broader first episode psychosis literature raises questions about the appropriateness of the terminology “non-affective psychosis” to describe a condition in which affect disturbance is such a common associated feature.

4.1. Limitations and directions for future research

The current study is limited to a cross-sectional, baseline clinical snapshot and cannot offer insight into the trajectories of mood disturbance over time in individuals at risk for psychosis. Retrospective diagnoses of remitted depression were obtained using a SCID at the time of baseline assessment, so the accuracy of these diagnoses may be less than optimal. Similarly, the lack of information about the temporal onset of psychotic and depressive symptoms, as well as the timing of medication exposure relative to symptom onset, are limitations. This study is also somewhat limited by the fact that participants in NAPLS represent for the most part a help-seeking group, which likely differs both clinically and demographically from the total population of individuals prodromal to schizophrenia.
and other psychoses in the community (Woodberry et al., 2016a). Finally, NAPLS-2 used the SIPS to define CHR status, and thus the sample may not align with high-risk samples identified using alternative psychosis-risk criteria. Future research is needed to examine the impact of depression on selection and effectiveness of treatment for individuals at CHR for psychosis.

5. Conclusions

The current study adds to the existing literature by examining the concurrent impact and prognostic meaning of depression within a large cohort of newly diagnosed CHR participants. This work complements recent research establishing individualized risk prediction from clinical and neuropsychological factors that can easily be assessed in individuals meeting SIPS criteria for high risk states (see Cannon et al., 2016; Carrión et al., 2016). Within this cohort, a diagnosis of depression was associated with more pronounced negative and general symptoms, indicating exacerbations in sleep and mood problems, poor stress tolerance, and decreased hygiene. Current (symptomatic, rather than diagnostic) depressed mood contributed beyond the impact of positive and negative symptoms to impairments in social functioning. Individuals with remitted depression had significantly less severe negative and general symptoms, and better social and role functioning, relative to those with current depression. A diagnosis of current or past depression was also associated with greater prior exposure to antidepressant and antipsychotic medications, a possibly proxy for past treatment seeking. Those with less depression at baseline were more likely to achieve CHR remission over time. These findings suggest that absence of depression in CHR serves as a marker of good prognosis, and that treatment for depression in CHR states may be helpful for reducing disability and improving social functioning.

Acknowledgments

Robert Heinssen, PhD, of the National Institute of Mental Health, provided study support. We would like to acknowledge Victoria Choate Hasler, Michelle Friedman-Yakobian, Anthony Giuliano, Andrea Gnong-Granato, Matthew S. Keshavan, Robert W. McCarley, Raquelle Mesholam-Gately, Jayne-Marie Nova, Corin Pilo-Comtois, Janine Rodenhisler-Hill, Rachael Serur, Lynda Tucker, and Joanne Wojcik for their valued assistance with the study at the Beth Israel Deaconess Medical Center site. We are grateful to the many staff at the eight participating sites and the participants who contributed to this study.

Role of the funding source

This study was supported by the National Institute of Mental Health (NIMH) grants U01 MH081928, and the Commonwealth of Massachusetts SCDMH82101008006 to Dr. Seidman; grant U01 MH081984 to Dr. Addington; grants R01 MH60720, U01 MH082022 and K24 MH76191 to Dr. Cadenhead; grant U01 MH081902 to Dr. Cannon; P50 MH066286 (Prodromal Core) to Dr. Bearden; U01 MH081857 grant to Dr. Cornblatt; grant U01 MH082004 to Dr. Perkins; grant U01 MH081988 to Dr. Walker; grant U01 MH082022 to Dr. Woods; Clinical Translational Science Award (UL1RR025758) and General Clinical Research Center Grant (M01RR01032) from the National Center for Research Resources to Harvard University and Beth Israel Deaconess Medical Center, the National Center for Research Resources (P41RR14075), and Shared Instrumentation Grants (1S10RR023401, 1S10RR019307, 1S10RR023043). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The NIMH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Schizophr Res. Author manuscript; available in PMC 2019 February 01.
References


Carrióñ RE, Cornblatt BA, Burton CZ, Tso IF, Author AM, Adelsheim S, ... Taylor SF, 2016 Personalized prediction of psychosis: external validation of the NAPLS-2 psychosis risk calculator with the EDIPPP project. Am. J. Psychiatry 173 (10), 989–996. [PubMed: 27363511]


Fig. 1.
Depressive disorders in NAPLS-2.
Table 1  

Lifetime medication exposure among CHR participants with and without depression.

<table>
<thead>
<tr>
<th></th>
<th>Lifetime depression&lt;sup&gt;a&lt;/sup&gt; (n = 444)</th>
<th>No lifetime depression (n = 300)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antipsychotics (%)</td>
<td>28</td>
<td>22</td>
</tr>
<tr>
<td>Antidepressants (%)</td>
<td>50&lt;sup&gt;b&lt;/sup&gt;</td>
<td>29</td>
</tr>
<tr>
<td>Mood stabilizers (%)</td>
<td>7</td>
<td>11&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Stimulants (%)</td>
<td>20</td>
<td>25</td>
</tr>
<tr>
<td>Benzodiazepines (%)</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>Any medication (%)</td>
<td>63&lt;sup&gt;b&lt;/sup&gt;</td>
<td>54</td>
</tr>
</tbody>
</table>

<sup>a</sup>Includes participants with current or past depressive episode, per SCID criteria.  

<sup>b</sup>Chi-square test indicates significant difference (p < 0.05).
Table 2
Symptoms and functional impairments in CHR participants with and without depression.

<table>
<thead>
<tr>
<th></th>
<th>Never depressed</th>
<th>Ever depressed&lt;sup&gt;d&lt;/sup&gt;</th>
<th>ANOVA Result</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(N = 300)</td>
<td>(N = 444)</td>
<td>F</td>
<td>p</td>
<td>Effect size</td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive symptoms</td>
<td>11.97 (3.65)</td>
<td>11.79 (3.97)</td>
<td>0.96</td>
<td>0.33</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>Negative symptoms&lt;sup&gt;b&lt;/sup&gt;</td>
<td>5.88 (4.06)</td>
<td>7.25 (3.97)</td>
<td>23.74</td>
<td>&lt;0.01</td>
<td>0.36</td>
<td></td>
</tr>
<tr>
<td>Disorganized symptoms</td>
<td>5.08 (3.14)</td>
<td>5.22 (3.16)</td>
<td>0.34</td>
<td>0.56</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>General symptoms</td>
<td>7.89 (4.02)</td>
<td>10.00 (4.23)</td>
<td>40.78</td>
<td>&lt;0.01</td>
<td>0.47</td>
<td></td>
</tr>
<tr>
<td>Global functioning: social</td>
<td>6.59 (1.65)</td>
<td>6.08 (1.53)</td>
<td>16.18</td>
<td>&lt;0.01</td>
<td>0.31</td>
<td></td>
</tr>
<tr>
<td>Global functioning: role</td>
<td>6.17 (2.06)</td>
<td>5.96 (2.25)</td>
<td>2.56</td>
<td>0.11</td>
<td>0.13</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Remitted depression</th>
<th>Current depression</th>
<th>ANOVA Result</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(N = 130)</td>
<td>(N = 314)</td>
<td>F</td>
<td>p</td>
<td>Effect size</td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive symptoms</td>
<td>11.82 (4.12)</td>
<td>11.78 (3.92)</td>
<td>&lt;0.01</td>
<td>0.99</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Negative symptoms&lt;sup&gt;b&lt;/sup&gt;</td>
<td>6.08 (3.60)</td>
<td>7.72 (4.02)</td>
<td>14.76</td>
<td>&lt;0.01</td>
<td>0.37</td>
<td></td>
</tr>
<tr>
<td>Disorganized symptoms</td>
<td>4.68 (2.86)</td>
<td>5.43 (3.25)</td>
<td>5.27</td>
<td>0.02</td>
<td>0.22</td>
<td></td>
</tr>
<tr>
<td>General symptoms</td>
<td>8.03 (4.04)</td>
<td>10.79 (4.04)</td>
<td>45.44</td>
<td>&lt;0.01</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td>Global functioning: social</td>
<td>6.36 (1.49)</td>
<td>5.96 (1.54)</td>
<td>5.74</td>
<td>0.01</td>
<td>0.24</td>
<td></td>
</tr>
<tr>
<td>Global functioning: role</td>
<td>6.37 (2.14)</td>
<td>5.80 (2.28)</td>
<td>5.11</td>
<td>0.01</td>
<td>0.22</td>
<td></td>
</tr>
</tbody>
</table>

SOPS items (Positive, Negative, Disorganized, General) scored 0–6; higher scores represent more severe symptoms.

Global Functioning scales scored 1–10; higher scores represent better functioning.

<sup>a</sup>Includes participants with current or past depressive episode, per SCID criteria.

<sup>b</sup>Does not include N1 or N6 so as to avoid overlap with GF-S/R constructs.
Table 3
Regression analyses predicting social and role functioning.

<table>
<thead>
<tr>
<th></th>
<th>Entire CHR sample (N = 744)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>GF-social</strong></td>
<td><strong>GF-role</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>R = 0.37, F = 35.27, p &lt; 0.001</strong></td>
<td><strong>R = 0.31, F = 23.71, p &lt; 0.001</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>β</strong></td>
<td><strong>t</strong></td>
<td><strong>p</strong></td>
<td><strong>β</strong></td>
</tr>
<tr>
<td>Constant</td>
<td>N/A</td>
<td>35.32</td>
<td>&lt;0.001</td>
<td>N/A</td>
</tr>
<tr>
<td>P-total</td>
<td>0.06</td>
<td>1.50</td>
<td>0.133</td>
<td>0.03</td>
</tr>
<tr>
<td>N-total^a</td>
<td>−0.30</td>
<td>−7.79</td>
<td>&lt;0.001</td>
<td>−0.32</td>
</tr>
<tr>
<td>CDSS total</td>
<td>−0.16</td>
<td>−4.17</td>
<td>&lt;0.001</td>
<td>0.01</td>
</tr>
</tbody>
</table>

|                      | CHR participants with lifetime (current or past) depression only (N = 444) |                      |                      |                      |
|                      | **GF-social**                                                      | **GF-role**          |                      |                      |
|                      | **R = 0.33, F = 16.14, p < 0.001**                                  | **R = 0.28, F = 11.42, p < 0.001** |                      |                      |
|                      | **β**                  | **t**           | **p**                | **β**                  | **t**           | **p**                |
| Constant             | N/A                    | 26.37           | <0.001               | N/A                    | 18.06           | <0.001               |
| P-total               | 0.10                   | 2.03            | 0.043                | 0.06                   | 1.19            | 0.236                |
| N-total^a             | −0.29                  | −5.66           | <0.001               | −0.28                  | −5.47           | <0.001               |
| CDSS total            | −0.10                  | −2.03           | 0.043                | −0.01                  | −0.28           | 0.783                |

^aDoes not include N1 or N6.